Lv11
42 积分 2021-08-18 加入
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study
2天前
已完结
Milvexian for the Prevention of Venous Thromboembolism
2天前
已完结
Tertiary lymphoid structures in cancer
11天前
已完结
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities
14天前
已完结
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
22天前
已完结
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study
24天前
已完结
Efficacy and Safety of Atezolizumab Monotherapy or Combined Therapy with Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
25天前
已完结
Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC
28天前
已完结
A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer
29天前
已完结
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
1个月前
已完结
皖公网安备34019202002308
